X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs FRESENIUS KABI ONCO. - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. FRESENIUS KABI ONCO. WOCKHARDT LTD./
FRESENIUS KABI ONCO.
 
P/E (TTM) x -18.2 22.1 - View Chart
P/BV x 3.0 3.1 95.9% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 WOCKHARDT LTD.   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
FRESENIUS KABI ONCO.
Mar-13
WOCKHARDT LTD./
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,129176 641.5%   
Low Rs62779 798.7%   
Sales per share (Unadj.) Rs363.137.7 963.6%  
Earnings per share (Unadj.) Rs-20.45.1 -401.5%  
Cash flow per share (Unadj.) Rs-7.06.7 -103.7%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs301.842.5 709.4%  
Shares outstanding (eoy) m110.55158.23 69.9%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x2.43.4 71.6%   
Avg P/E ratio x-42.925.0 -171.9%  
P/CF ratio (eoy) x-125.918.9 -665.1%  
Price / Book Value ratio x2.93.0 97.3%  
Dividend payout %-48.90-   
Avg Mkt Cap Rs m97,06320,135 482.1%   
No. of employees `0006.81.2 587.5%   
Total wages/salary Rs m9,665703 1,374.4%   
Avg. sales/employee Rs Th5,931.85,176.2 114.6%   
Avg. wages/employee Rs Th1,428.1610.4 233.9%   
Avg. net profit/employee Rs Th-334.0699.6 -47.7%   
INCOME DATA
Net Sales Rs m40,1465,963 673.3%  
Other income Rs m1,14318 6,347.2%   
Total revenues Rs m41,2895,981 690.3%   
Gross profit Rs m1281,430 9.0%  
Depreciation Rs m1,489258 577.5%   
Interest Rs m2,253-26 -8,664.2%   
Profit before tax Rs m-2,4721,216 -203.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m-211342 -61.7%   
Profit after tax Rs m-2,260806 -280.5%  
Gross profit margin %0.324.0 1.3%  
Effective tax rate %8.528.1 30.4%   
Net profit margin %-5.613.5 -41.7%  
BALANCE SHEET DATA
Current assets Rs m46,1605,102 904.8%   
Current liabilities Rs m19,2582,385 807.3%   
Net working cap to sales %67.045.6 147.1%  
Current ratio x2.42.1 112.1%  
Inventory Days Days101150 67.1%  
Debtors Days Days94113 83.0%  
Net fixed assets Rs m40,1655,148 780.2%   
Share capital Rs m553158 349.4%   
"Free" reserves Rs m32,8146,556 500.6%   
Net worth Rs m33,3676,732 495.7%   
Long term debt Rs m31,903952 3,350.4%   
Total assets Rs m89,68710,388 863.4%  
Interest coverage x-0.1-45.8 0.2%   
Debt to equity ratio x1.00.1 675.9%  
Sales to assets ratio x0.40.6 78.0%   
Return on assets %07.5 -0.1%  
Return on equity %-6.812.0 -56.6%  
Return on capital %-0.314.6 -2.3%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m9,1215,298 172.2%   
Fx outflow Rs m2,1331,772 120.4%   
Net fx Rs m6,9883,525 198.2%   
CASH FLOW
From Operations Rs m-2,6951,274 -211.5%  
From Investments Rs m-6,863-1,204 569.9%  
From Financial Activity Rs m12,545-196 -6,397.2%  
Net Cashflow Rs m3,010-126 -2,383.5%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 2.3 0.3 766.7%  
FIIs % 7.7 9.6 80.2%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 9.1 169.2%  
Shareholders   67,757 42,599 159.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   MERCK LTD  CIPLA  TORRENT PHARMA  SUVEN LIFE  WYETH LTD  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Jan 19, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - GLENMARK PHARMA COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS